The reaction of pyrazolo[1,5-a]pyrazine-4(5H)ones with phosphorus tribromoxide in boiling benzene yielded 4-bromopyrazolo[1,5-a]pyrazines, and the thionation with phosphorus pentasulfide in pyridine at 90 °C led to pyrazolo[1,5-a]pyrazine-4(5H)thiones. The synthesized bromine derivatives are electrophilic, and thiones are nucleophilic substrates. Their subsequent structural modification in the first case was carried out by interaction with thiophenols, and in the second case was conducted with functional halogenoalkanes. It was shown that bromides react with substituted thiophenols in dimethylformamide in the presence of potassium carbonate at 90 °C to form 4-arylthiopyrazolo[1,5-a]pyrazines with yields of 65–83 %. 4-S-methyl-functionalized derivatives of pyrazole[1,5-a]pyrazines with yields of 60–78 % were easily obtained by the alkylation of pyrazole[1,5-a]pyrazin-4(5H)thiones with a-bromoketones, bromoacetic acid, ethyl bromoacetate and bromoacetonitrile in the K2CO3—DMF system at room temperature. The composition of all synthesized compounds is in agreement with the results of elemental analysis and mass spectra. Their structure is confirmed by NMR 1H and 13C spectra. In particular, in the NMR 1H spectra of 4-arylthiopyrazolo[1,5-a]pyrazines, in addition to the characteristic signals of the pyrazole and pyrazine nuclei, signals of protons of thioaryl substituents are present in the range of 7.04 –8.05 ppm, and in NMR spectra of the 1H 4-S-methylfunctionalized derivatives of pyrazole[1,5-a]pyrazines signals of exocyclic methylene protons are present at 4.11– 5.02 ppm. Promising derivatives with antibacterial activity against the test cultures S. aureus (MIC = 7.8 g/mL), M. luteum (MIC = 3.9 g/mL), and antifungal activity against the test culture of fungus A. niger (MIC = 7.8 g/mL) were determined among 4-S-substituted pyrazole[1,5-a]pyrazines as a result of studies of the antimicrobial activity.
Abdul‐Malik M. A., Zaki R. M., Kamal El‐Dean A. M., Radwan S. M. A Concise Review on the Synthesis and Reactions of Pyrazolopyrazine Heterocycles. J. Het.Chem. 2018, 55: 1828.
Pennington L. D., Moustakas D. T. The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. J.Med.Chem. 2017, 60(9): 3552.
Zhenga L.-W., Shao J.-H., Zhao B.-X., Miao J.-Y. Synthesis of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives and their inhibition against growth of A549 and H322 lung cancer cells. Bioorg. Med. Chem. Lett. 2011, 21(13): 3909.
Patent WO 101161. Bach Tana J., Pages Santacana L. M., Taltavull Moll J., Eastwood P. R., Gonzalez Rodrigues J., Giulio Matassa V. Pyrazole Derivatives as JAK Inhibitors. 2011.
Patent WO 141713. Pastor F. J., Martinez G. S., Rodrigues H. A., Ramos Lima F. J., Alvarez Escobar R. M., Higueras Hernandez A. I. 6 Substituted 2-Heterocyclylamino Pyrazine Compounds as CHK-1 Inhibitors. 2011.
Patent WO 016005. Ninkovic S., Braganza J. F., Collins M. R., Kath J. C., Li H., Richter D. T. 6 Substituted 2-Heterocyclylamino Pyrazine Compounds as CHK-1 Inhibitors. 2010.
Patent WO 166370. Gray D. L. F., Davoren J. E., Dounay A. B., Efremov I. V., Mente S. R., Subramanyam C. Heteroaromatic Compounds and Their Use as Dopamine D1 Ligands. 2015.
Ting P. C., Lee J. F., Albanese M. M., Wu J., Aslanian R., Favreau L., Nardo C., Korfmacher W. A., West R. E., Williams S. M., Anthes J. C., Rivelli M. A., Corboz M. R., Heyc J. A. The synthesis and structure–activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists. Bioorg. Med. Chem. Lett. 2010, 20(17): 5004.
Patent WO 130232. Di Fabio R., Gentile G., Pozzan A.,Tarsi L., Terreni S., Tonelli F. Pyrazolo[1,5-a]pyrazine Derivatives as Antagonists of V1B Receptors. 2009.
Patent WO 1011119. Liverton N., Kuduk S.D., Beshore D.C., Meng N., Luo Y. Fused heteroaryl derivatives as orexin receptor antagonists. 2016.
Patent WO 119916. Qi, H., Choi, S., Dakka, A., Karp G. M., Narasimhan J., Naryshkin N., Turpoff A. A., Weetall M. L. Welch E., Woll M. G., Yang T., Zhang N., Zhang X., Zhao X., Green L., Pinard E., Ratni H. Compounds for treating spinal muscular atrophy. 2013.
Woll, M. G., Qi, H., Turpoff, A., Zhang N., Zhang X., Chen G., Li C., Huang S., Yang T., Moon Y.-C., Lee C.-S., Choi S., Almstead N.G., Naryshkin N.A., Dakka A., Narasimhan J., Gabbeta V., Welch E., Zhao X., Risher N., Sheedy J., Weetall M., Karp G.M. Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 as a treatment for spinal muscular atrophy. J. Med.Chem. 2016, 59(13): 6070.
Shen S.-L., Zheng L.-W., Wang S.-Q., Zhang Y.-R., Zhang Y., Liu Y. R., Zhao B.-X. Solvent-free microwave-assisted synthesis of tetrahydrooxazolo[3,2-a]pyrazolo[1,5-d]pyrazin-5-ones. ARKIVOC, 2013, 4: 44.
Patent 4077956 USA. Treuner U. D. 5-Substituted Derivatives of Dipyrazolo[1,5-a:4’,3’-e]pyrazine-6-carboxylic Acids and Esters. 1978.
Patent 4128716 USA. Treuner U. D. 4-Halo Derivatives of Pyrazolo[1,5-a]quinoxaline-3-carboxylic Acids and Esters. 1978.
Patent 4052393 USA. Treuner U. D. 4-Substituted Derivatives of Pyrazolo[1,5-a]quinoxaline-3-carboxylic Acids and Esters. 1977.
Hrynyshyn Y. V., Tsyzoryk N. M., Musiychuk A. R., Bol'but A. V., Vovk M. V. Synthesis of 8H-pyrazolo[5’,1’:3,4]pyrazino[2,1-b]quinazolin-8-ones. Chem. Heterocycl. Compd. 2017, 53(11): 1242.
Performance Standards for Antimicrobial Disk Susceptibility Tests – 4-th Edition: Approved Standards, Document M2-A4, NCCLS.Villanova. PA, 1990.
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi: Proposed Standard, Document M38-P, NCCLS.Wayne. PA, 1998.